Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017
February 14, 2017 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth-quarter 2016 financial results on Tuesday, February 28, 2017, after the close of the U.S....
Tesaro Announces Participation in Three Investor Conferences
November 21, 2016 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor...
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer
November 01, 2016 16:30 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 01, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has completed the niraparib rolling New Drug...
TESARO Announces Acceptance for Review of Niraparib Marketing Authorization Application by EMA
October 27, 2016 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
TESARO and ENGOT Announce Presentation of Successful Niraparib Phase 3 ENGOT-OV16/NOVA Trial Results During ESMO 2016
October 08, 2016 02:15 ET
|
TESARO, Inc.
Simultaneous presentation of data at ESMO and publication online in the New England Journal of MedicineTESARO Investor Webcast to be Held at 7:00 PM CET / 1:00 PM EDT COPENHAGEN, Oct. 08, 2016 ...
TESARO Announces First-Quarter 2016 Operating Results
May 05, 2016 16:05 ET
|
TESARO, Inc.
U.S. launch of VARUBI® underway; New Drug Application (NDA) for IV formulation of rolapitant submittedNiraparib Phase 3 NOVA results anticipated in Q2 2016 are positioned to be the first data from a...
TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors
April 04, 2016 08:00 ET
|
TESARO, Inc.
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P....
TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
March 14, 2016 08:05 ET
|
TESARO, Inc.
WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
TESARO Outlines Business Priorities and Strategic Outlook for 2016
January 11, 2016 08:15 ET
|
TESARO, Inc.
U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned...